Sector News

Lars Dreiøe joins Sobi as Senior VP, Chief Quality & Compliance Officer

December 22, 2015
Life sciences

Swedish Orphan Biovitrum AB (Sobi) today announced that Lars Dreiøe has been appointed Senior Vice President Chief Quality & Compliance Officer (CQCO). Lars Dreiøe joins Sobi from global pharmaceutical company ALK in Denmark where he has been International Head of Quality.

Lars brings 20 years of experience in the Biotech and Pharmaceutical industry in the Quality, Manufacturing, Product Safety and Regulatory Affairs areas.

“We are delighted to welcome Lars to Sobi”, said Geoffrey McDonough, President and CEO at Sobi. “Sobi has been expanding the scope and geographic area of operations and the demands and complexity of external regulations governing our business has also increased. Lars will sustain and deepen our global commitment to quality in all aspects of our work, and will be a valuable addition to our senior leadership team.”

“I’m very much looking forward to joining the team at Sobi and to entering my new role – developing and delivering therapies at the highest level of quality to people living with a rare disease,” said Lars Dreiøe.

Lars will join Sobi on 18 January 2016.

Source: Swedish Orphan Biovitrum AB

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend